龚艳君,陈丽珠,洪涛,陈明,李建平,刘兆平,霍勇

• 1:北京大学第一医院心内科
• 2:包头医学院第一附属医院心内科

摘要(Abstract)：

目的观察替罗非班对急性ST段抬高心肌梗死(STEMI)患者急诊经皮冠状动脉介入治疗(PCI)术后远期预后的影响。方法分析2008年1月至2010年9月行急诊PCI的急性STEMI患者228例,根据围术期是否使用替罗非班分为替罗非班组(173例)和对照组(55例)。观察两组患者住院期间和随访期间(6个月至36个月)主要不良心血管事件(MACE)的发生情况。结果替罗非班组与对照组相比,两组患者术中无复流的发生、术后即刻达到TIMI血流分级Ⅲ级、心肌染色分级(MBG)3级和心电图ST段回落大于50%的比例比较,差异均无统计学意义;两组患者住院期间总MACE、死亡、非致死性心肌梗死、计划外再次血运重建的发生率的差异均无统计学意义(P>0.05),而替罗非班组心功能不全的发生率低于对照组(16.2%比30.9%,P=0.017)。随访期间替罗非班组总MACE(4.7%比13.5%,P=0.029)、计划外再次血运重建(3.6%比13.5%,P=0.008)和因心脏原因再住院(17.2%比30.8%,P=0.033)的发生率均低于对照组,而两组间死亡、非致死性心肌梗死发生率比较,差异无统计学意义(P>0.05)。Cox回归分析显示使用替罗非班可降低患者远期MACE的发生率(OR 0.357,95%CI 0.130~0.985,P=0.047)。结论替罗非班具有改善急性STEMI患者急诊PCI术后远期预后的潜在作用。

关键词(KeyWords)： 急性ST段抬高心肌梗死;替罗非班;急诊介入治疗;远期预后

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 龚艳君,陈丽珠,洪涛,陈明,李建平,刘兆平,霍勇

参考文献(References)：

• [1]van't Hof AW,Ten Berg J,Heestermans T,et al.Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty(On-TIME 2):a multicentre,double-blind,randomised controlled trial.Lancet,2008,372:537-546.
• [2]Mrdovic I,Savic L,Lasica R,et al.Efficacy and safety of tirofiban-supported primary percutaneous coronary intervention in patients pretreated with 600 mg clopidogrel:results of propensity analysis using the Clinical Center of Serbia STEMI Register.Eur Heart J Acute Cardiovasc Care,2014,3:56-66.
• [3]钱翠平,彭稳中,张予,等.Meta分析:冠状动脉应用替罗非班用于急性冠状动脉综合征经皮冠状动脉介入治疗的疗效.中国介入心脏病学杂志,2014,22:237-245.
• [4]van't Hof AW,Liem A,Suryapranata H,et al.Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction:myocardial blush grade.Zwolle Myocardial Infarction Study Group.Circulation,1998,97:2302-2306.
• [5]O'Gara PT,Kushner FG,Ascheim DD,et al.2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.J Am Coll Cardiol,2013,61:e78-e140.
• [6]Steg PG,James SK,Atar D,et al.ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.Eur Heart J,2012,33:2569-2619.
• [7]Liu Y,Su Q,Li L.Safety and efficacy of early administration of tirofiban in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention:a meta-analysis.Chin Med J(Engl),2014,127:1126-1132.
• [8]De Luca G,Bellandi F,Huber K,et al.Early glycoprotein IIbIIIa inhibitors in primary angioplasty-abciximab long-term results(EGYPT-ALT)cooperation:individual patient's data metaanalysis.J Thromb Haemost,2011,9:2361-2370.
• [9]Valgimigli M,Biondi-Zoccai G,Tebaldi M,et al.Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention:a meta-analysis of randomized trials.Eur Heart J,2010,31:35-49.
• [10]Zhu J,Zhang T,Xie Q,et al.Effects of upstream administration of tirofiban before percutaneous coronary intervention on spontaneous reperfusion and clinical outcomes in acute STsegment elevation myocardial infarction.Angiology,2015,66:70-78
• [11]唐强,霍勇,陈明,等.盐酸替罗非班对急性心肌梗死急诊经皮冠状动脉介入治疗中TIMI血流影响的临床研究.中国介入心脏病学杂志,2006,14:97-99.
• [12]Lavi S,Gruberg L,Kapeliovich M,et al.The impact of GPⅡb/Ⅲa inhibitors during Primary Percutaneous coronary intervention in acute myocardial infarction Patients.J Invasive Cardiol,2005,17:296-299.
• [13]ten Berg JM,van't Hof AW,Dill T,et al.Effect of Early,PreHospital Initiation of High Bolus Dose Tirofiban in Patients With ST-Segment Elevation Myocardial Infarction on Short-and LongTerm Clinical Outcome.J Am Coll Cardiol,2010,55:2446-2455.